ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.
What happened
FDA inspected ExThera from May 27, 2025, to June 4, 2025, as sponsor of two significant-risk investigational device exemption (IDE) studies. FDA found devices shipped for compassionate use without prior approval, no evidence that informed consent was verified for enrolled subjects, and public promotion of Seraph 100 as approved, safe, and effective even though it lacks premarket approval (PMA). FDA also cited the device as adulterated and misbranded based on its website and public statements.
What FDA found
The company shipped Seraph 100 devices for compassionate use, an unapproved treatment pathway, before getting FDA approval for the change to the study plan and did not report one emergency use as required.
21 CFR 812.35(a)(1)The company did not properly monitor the studies or secure investigator compliance, and it could not provide evidence that informed consent was signed for enrolled subjects.
21 CFR 812.40; 21 CFR 812.46(a)FDA says Seraph 100 is adulterated because ExThera lacks an approved premarket approval (PMA) or IDE for the device as marketed.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)FDA says the device is misbranded because ExThera did not submit the required premarket notification (510(k)) before commercial distribution.
section 502(o) of the Act, 21 U.S.C. § 352(o); 21 CFR 807.81FDA says ExThera made false or misleading statements about the device’s regulatory status.
section 502(a) of the Act, 21 U.S.C. § 352(a)FDA found the website claimed a safety profile consistent with standard extracorporeal labeling even though FDA had not determined the device safe for U.S. patients.
21 CFR 812.5(b); 21 CFR 812.7
What FDA wants
Within 15 working days, send FDA documentation of corrective and preventive actions, with completion dates and a plan to check effectiveness. FDA also asks ExThera to stop activities that misbrand or adulterate Seraph 100, revise its compassionate-use instruction, and account for distributed devices.
Who should pay attention
- clinical study sponsors and institutional review boards
- distributors or partners of investigational medical devices
- companies making promotional claims about unapproved devices
This is a summary. Read the original letter on fda.gov.